IDYAHIGH SIGNALFINANCIAL10-K

IDYA showed substantial improvement in financial performance with meaningfully reduced operating losses and significantly better cash flow from operations.

The company demonstrated notable progress in managing its cash burn, with operating cash flow losses substantially reduced compared to the prior year. This improvement, combined with higher cash balances, suggests better operational efficiency and extended runway for the biotech company's development programs.

Comparing 2026-02-17 vs 2025-02-18View on EDGAR →
FINANCIAL ANALYSIS

IDYA's financial position improved markedly across key metrics, with operating losses and net losses both substantially reduced year-over-year. Operating cash flow losses decreased meaningfully while the company maintained higher cash reserves, growing from $84.4M to $112.8M. The company also reduced capital expenditures while total liabilities increased modestly, reflecting a more disciplined approach to cash management during this development phase.

FINANCIAL STATEMENT CHANGES
Operating Cash Flow
Cash Flow
+71.3%
-$247.6M→-$71.1M

Operating cash flow surged 71.3% — exceptional cash generation, highest quality earnings signal.

Net Income
P&L
+58.6%
-$274.5M→-$113.7M

Net income grew 58.6% — bottom-line growth signals improving overall business health.

Operating Income
P&L
+51.3%
-$327.0M→-$159.3M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Capital Expenditure
Cash Flow
-38.6%
$3.9M→$2.4M

Capex reduced 38.6% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Cash & Equivalents
Balance Sheet
+33.7%
$84.4M→$112.8M

Cash position surged 33.7% — strong cash generation or capital raise providing significant financial cushion.

Total Liabilities
Balance Sheet
+33%
$64.9M→$86.4M

Liabilities grew 33% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Liabilities
Balance Sheet
+27.7%
$46.1M→$58.8M

Current liabilities rose 27.7% — increased short-term obligations, watch current ratio.

LANGUAGE CHANGES
NEW — 2026-02-17
PRIOR — 2025-02-18
ADDED
As of February 13, 2026, the registrant had 87,814,027 shares of common stock, $0.0001 par value per share, outstanding.
This number does not include 875,135 shares of common stock issuable upon the exercise of pre-funded warrants outstanding as of February 13, 2026 (which are immediately exercisable at an exercise price of $0.0001 per share of common stock, subject to beneficial ownership limitations).
(Gilead), our Clinical Trial Collaboration and Supply Agreements with Pfizer Inc.
(Pfizer), our License Agreement with Novartis, our Option and License Agreement with Cancer Research Technologies Ltd.
and the University of Manchester, our Option and License Agreement with Biocytogen ii Pharmaceuticals (Beijing) Co.
+7 more — sign up free →
REMOVED
As of February 14, 2025, the registrant had 87,537,391 shares of common stock, $0.0001 par value per share, outstanding.
We have incurred significant losses since our inception, and we anticipate that we will iii continue to incur significant losses for the foreseeable future, which, together with our limited operating history, makes it difficult to assess our future viability; We are early in our development efforts.
Furthermore, results of earlier studies and trials may not be predictive of future trial results; We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being developed.
This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts; We face significant competition in an environment of rapid technological and scientific change, and our failure to effectively compete may prevent us from achieving significant market penetration.
Most of our competitors have significantly greater resources than we do and we may not be able to successfully compete; If we fail to attract and retain senior management and key scientific and commercial personnel, our business may be materially and adversely affected; Our success depends on our ability to obtain and maintain protection for our intellectual property and our proprietary technologies and to avoid infringing the rights of others; and Our stock price may be volatile and you may not be able to resell shares of our common stock at or above the price you paid.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →